Cardio Diagnostics Holdings, Inc. (CDIO): Depreciation & Amortization
$65.2K
Year ended 2025-12-31
$22.4K
Trailing 12 months to 2026-06-30
+59.8%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $65.2K | +230.5% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $19.7K | +2.9% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $19.2K | +19.9% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $16.0K | 0.0% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $16.0K | n/a | 2023-03-31, From 2021-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | $65.2K | +230.5% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $3.38M | +6.4% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $983.7K | -11.6% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $2.19M | +48.4% |
| Biomerica Inc (BMRA) | 2026-05-31 | $77.0K | -11.5% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $112.0K | +21.7% |
| Immucell Corp (ICCC) | 2025-12-31 | $2.78M | +2.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $6.34M | -3.6% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $9.77M | -5.0% |
Compare CDIO, CLDX, VNRX, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗